Drugs targeting this pathway have achieved effective outcomes in the treatment of certain cancers with BRAF mutations, including colorectal cancer, hairy cell leukemia, melanoma, thyroid cancer, non-small cell lung cancer, etc. [40–44]. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.